Stephen Industries

StemSight is a Finnish biotechnology company developing innovative cell therapies for treating blindness. Its proprietary platform uses induced pluripotent stem cells (iPSCs) and biomaterials, initially targeting rare diseases like limbal stem cell deficiency, with plans to expand to major corneal blindness conditions.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.